The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Open accessAbstract
BACKGROUND: Bapineuzumab, a humanized anti-amyloid-beta (Abeta) monoclonal antibody for the potential treatment of Alzheimer disease (AD), was evaluated in a multiple ascending dose, safety, and efficacy study in mild to moderate AD. METHODS: The study enrolled 234 patients, randomly assigned to IV bapineuzumab or placebo in 4 dose cohorts (0.15, 0.5, 1.0, or 2.0 mg/kg). Patients received 6 infusions, 13 weeks apart, with final assessments at week 78. The prespecified primary efficacy analysis in the modified intent-to-treat population assumed linear decline and compared treatment differences within dose cohorts on the Alzheimer's Disease Assessment Scale-Cognitive and Disability Assessment for Dementia. Exploratory analyses combined dose cohorts and did not assume a specific pattern of decline. RESULTS: No significant differences were found in the primary efficacy analysis. Exploratory analyses showed potential treatment differences (p < 0.05, unadjusted for multiple comparisons) on cognitive and functional endpoints in study "completers" and APOE epsilon4 noncarriers. Reversible vasogenic edema, detected on brain MRI in 12/124 (9.7%) bapineuzumab-treated patients, was more frequent in higher dose groups and APOE epsilon4 carriers. Six vasogenic edema patients were asymptomatic; 6 experienced transient symptoms. CONCLUSIONS: Primary efficacy outcomes in this phase 2 trial were not significant. Potential treatment differences in the exploratory analyses support further investigation of bapineuzumab in phase 3 with special attention to APOE epsilon4 carrier status. CLASSIFICATION OF EVIDENCE: Due to varying doses and a lack of statistical precision, this Class II ascending dose trial provides insufficient evidence to support or refute a benefit of bapineuzumab.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Frequency of ARIA events and in particular ARIA-E was significantly higher among APOE ε4 allele carriers compared to non-carriers, making the APOE ε4 allele a risk factor for vascular complications of anti-Aβ immunotherapy [5, 8, 14, 15].”
From APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice (2017) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Frequency of ARIA events and in particular ARIA-E was significantly higher among APOE ε4 allele carriers compared to non-carriers, making the APOE ε4 allele a risk factor for vascular complications of anti-Aβ immunotherapy [5, 8, 14, 15].”
From APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice (2017) · cites this paper as [15]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Although clinical trials of the Aβ-directed mAb Bapinezumab showed no clear cognitive benefits in patients with mild to moderate AD [42], the results also indicated that APOE ε4 carrier status may limit the response to anti-Aβ passive immunization [43,44], as well as being associated with an increased rate of microbleeds and vasogenic edema [45].”
From Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement Alzheimer model mice (2014) · cites this paper as [44]
In the citing paper
“The greater incidence of these abnormalities with increasing bapineuzumab dose and number of APOEε4 alleles is consistent with phase 2 findings.11,13”
From Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease (2014) · cites this paper as [13]
In the citing paper
“in phase II trials, the anti-Aβ antibody bapineuzumab reduced CSF phospho-tau levels in patients with AD182,183”
From Tau-targeting therapies for Alzheimer disease (2018) · cites this paper as [183]
In the citing paper
“In fact, there have been hints of some beneficial effects (clinical and biochemical) linked to human anti-Aβ immunotherapies (74-79).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [76]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
Self-citationNeuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report
Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397
Strittmatter, W. J., Weisgraber, K. H., Huang, D. Y., Dong, L. M., Salvesen, G. S., Pericak-Vance, M., Schmechel, D., Saunders, A. M., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.8098 · Cited by 1,363
Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization
Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000073623.84147.a8 · Cited by 1,356
Self-citation
Cited by
Sorted by citations
Items 601–700 of 752
Translational research on disease‐modifying therapies for neurodegenerative diseases
Katsuno, M., Watanabe, H., Tanaka, F., & Sobue, G. (2013) · Neurology and Clinical Neuroscience · doi:10.1002/ncn3.7 · Cited by 4
Genspezifische Therapieansätze bei der Alzheimer-Krankheit und anderen Tauopathien
Feneberg, E., & Otto, M. (2020) · Der Nervenarzt · doi:10.1007/s00115-020-00872-6 · Cited by 4
Pilipovich, A. A., & Danilov, A. B. (2019) · Medical alphabet · doi:10.33667/2078-5631-2019-1-2(377)-35-42 · Cited by 4
Why is theNew York TimesWriting so Much about Alzheimer's Disease Therapies?
Bartfai, T. (2010) · The Scientific World JOURNAL · doi:10.1100/tsw.2010.185 · Cited by 4
New Lessons From the Alzheimer's Disease Neuroimaging Initiative
Salloway, S. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.344 · Cited by 4
Self-citationOosthoek, M., Vijverberg, E. G. B., Blujdea, E. R., Veld, S. G. J. G. I. ‘., Avilés, M. P., Zsadanyi, S. E., Hok‐A‐Hin, Y. S., Visser, A., van der Flier, W. M., Barkhof, F., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01799-3 · Cited by 3
alzheimer disease: New Concepts on Its Neurobiology and the Clinical
Jack, C. R., & Cme, O. (2012) · Cited by 3
Alzheimer's Disease: Clinical Trials and Future Perspectives
Lee, K. S., & Suh, H. S. (2012) · 대한정신약물학회지 · Cited by 2
Imaging spectrum of amyloid-related imaging abnormalities associated with aducanumab immunotherapy
Sotoudeh, H., Alizadeh, M., Shahidi, R., Shobeiri, P., Saadatpour, Z., Wheeler, C. A., Love, M. N., & Tanwar, M. (2024) · Frontiers in Radiology · doi:10.3389/fradi.2023.1305390 · Cited by 4
Structural MRI in Alzheimer’s Disease
Last, B. S., Rizvi, B. M., & Brickman, A. M. (2020) · Oxford University Press eBooks · doi:10.1093/oso/9780190634230.003.0010 · Cited by 3
Royal jelly - a potential for healthy lifestyle
Chander, I. N., & Lovleen (2021) · Journal of Entomological Research · doi:10.5958/0974-4576.2021.00126.2 · Cited by 3
Puerto, A. M. H., Russo, C., & Fregni, F. (2018) · Neuromethods · doi:10.1007/978-1-4939-7880-9_9 · Cited by 5
Therapeutics of Alzheimer’s Disease
Herrera-Rivero, M., & Emiliano, G. (2011) · InTech eBooks · doi:10.5772/27990 · Cited by 3
Alzheimer's disease: new therapies and the role of biomarkers.
Dudash, K. (2011) · PubMed Central · Cited by 3
Xu, S. X., Samtani, M. N., Russu, A., Adedokun, O. J., Lu, M., Ito, K., Corrigan, B., Raje, S. V., Brashear, H. R., Styren, S. D., et al. (2015) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2015.06.005 · Cited by 3
Addressing the Complex Etiology of Alzheimer‘s Disease: the Role of P25/Cdk5
Mungenast, A. E., & Tsai, L. (2011) · Future Neurology · doi:10.2217/fnl.11.22 · Cited by 3
Cerebral Amyloid Angiopathy-Related Inflammation Biomarkers: Where are we Now?
Charidimou, A. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151042 · Cited by 3
Chaudhary, V., Nigam, A. K., Paliwal, A., Singh, M. K., Gour, J. K., & Sinha, V. B. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819212-2.00005-0 · Cited by 4
Jasmin, S. B. (2011) · eScholarship@McGill (McGill) · doi:10.82308/52384 · Cited by 3
Clarke, E., Sinclair, L., Fletcher, E. J. R., Krawczun-Rygmaczewska, A., Duty, S., Stocki, P., Rutkowski, J. L., Doherty, P., & Walsh, F. S. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.12.987313 · Cited by 3
Kumar, N., & Bedi, P. M. S. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3529875 · Cited by 3
Agosta, F., Cecchetti, G., Spinelli, E. G., Ghirelli, A., Rugarli, G., & Filippi, M. (2025) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001388 · Cited by 2
Wu, S., Qi, Y., Jiang, C., & Zheng, J. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2448205 · Cited by 2
Biomarkers in Alzheimer’s Disease—Perspectives for the Future
Cummings, J. L. (2010) · touchREVIEWS in Neurology · doi:10.17925/usn.2010.06.01.23 · Cited by 2
Biomarker utility in Alzheimer's disease clinical trials
Soares, H. D., & Lovestone, S. (2013) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2013.09.002 · Cited by 2
Morelli, L., Perry, G. L., & Tagliavini, F. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/709613 · Cited by 2
Alzheimer’s disease vaccines: promises and pitfalls
Tabira, T. (2011) · Clinical Investigation · doi:10.4155/cli.11.71 · Cited by 2
L’immunothérapie dans la maladie d’Alzheimer : le point en 2012
Belmin, J., & Pariel, S. (2012) · NPG. Neurologie, psychiatrie, gériatrie/NPG · doi:10.1016/j.npg.2012.04.004 · Cited by 2
Microbleeds in relation to specific populations, diseases and neurological symptoms
Werring, D. J. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511974892.012 · Cited by 2
Immunotherapy in Alzheimer’s Disease
Gupta, J., & Hoque, M. (2019) · Springer eBooks · doi:10.1007/978-981-13-9636-6_14 · Cited by 2
Arakha, M., & Jha, S. (2018) · Series in bioengineering · doi:10.1007/978-3-319-73326-5_1 · Cited by 2
Deshpande, R. (2022) · Medicinal & Analytical Chemistry International · doi:10.23880/macij-16000174 · Cited by 1
Advances in the Treatment of Alzheimer's Disease
Rafii, M. S. (2012) · Wiley eBooks · doi:10.1002/9781119967309.ch10 · Cited by 2
Inhibitors of Amyloid and Oligomer Formation
Lorenzen, N., Wanker, E. E., & Otzen, D. E. (2013) · Wiley eBooks · doi:10.1002/9783527654185.ch16 · Cited by 2
Qiu, Y.-H., Liu, M., Zhan, J., Liu, L., Zheng, J., Wu, D., Wu, G., Cai, Y., & Zhang, S. (2023) · medRxiv · doi:10.1101/2023.11.20.23298794 · Cited by 2
Antibodies against Alzheimer's: Pioneering a New Era in Treatment Strategies
Verma, M., Singh, N. K., & Siddique, M. U. M. (2025) · Current Bioactive Compounds · doi:10.2174/0115734072347198241226113039 · Cited by 1
Study on Different Clinical Trial: A Comprehensive Review
Chaure, S. R., Bachhav, R. L., Deore, R. K., Surana, K. R., & Mahajan, S. K. (2025) · Asian Journal of Pharmacy and Technology · doi:10.52711/2231-5713.2025.00012 · Cited by 1
Evolving Pharmacotherapies Involving Neuroimmune Crosstalk
Maurya, R., Ali, K., Soni, H., Mhatre, A., & Naqvi, S. (2026) · Springer eBooks · doi:10.1007/978-981-95-5088-3_12 · Cited by 1
Sharma, A., Suresh, V., Kola, P. R., Raj, R. A., Javairia, F., Nithyanandam, A., Kaur, A., Arora, H., Uwishema, O., Gorty, D., et al. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261466097 · Cited by 3
An Overview of Target Specific Neuro-Protective and Neuro-Restorative Strategies
Al, A., Al, K., Al-, A., Arshaduddin, M., & Tariq, M. (2012) · InTech eBooks · doi:10.5772/34731 · Cited by 1
The central role of T-cell memory in Alzheimer’s disease vaccination
Giunta, B. N., Ruscin, A., Salemi, J., Wolfson, A., Fernandez, F., & Tan, J. (2010) · Ageing Research · doi:10.4081/ar.2010.e5 · Cited by 1
O’Donovan, J. (2011) · Reviews in Clinical Gerontology · doi:10.1017/s0959259811000141 · Cited by 1
New progress in active immunotherapy targeting to amyloid beta
Gao, L., Chen, Y., & Li, Y. (2015) · Science China Chemistry · doi:10.1007/s11426-014-5310-9 · Cited by 1
Thérapeutiques en regard des anomalies physiopathologiques de la maladie d’Alzheimer
Delrieu, J., Piau, A., & Vellas, B. J. (2011) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2011.03.005 · Cited by 1
Amyloid-Related Imaging Abnormalities Associated With Immunotherapy In Alzheimer‘s Disease Patients
Panza, F., Frisardi, V., Imbimbo, B. P., Logroscino, G., Seripa, D., Pilotto, A., & Solfrizzi, V. (2012) · Future Neurology · doi:10.2217/fnl.12.42 · Cited by 1
Passive immunisation with monoclonal anti-Abeta antibodies for the treatment of Alzheimer's disease
McCleery, J. M., Molena, E. J., & Worrall, R. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010188 · Cited by 1
RetractedLes réponses immunitaires adaptatives contre le peptide amyloïde Aβ dans la maladie d’Alzheimer
Dorothée, G., & Aucouturier, P. (2011) · médecine/sciences · doi:10.1051/medsci/20112711008 · Cited by 3
Translational Research in Alzheimer’s Disease for Development of Antibody-Based Therapeutics
Yuen, E., Liu, E., & Kinney, G. G. (2012) · Springer eBooks · doi:10.1007/978-1-4419-5955-3_14 · Cited by 1
Self-citationFuture Perspectives of Alzheimer Disease Research
Iwatsubo, T. (2011) · TRENDS IN THE SCIENCES · doi:10.5363/tits.16.7_57 · Cited by 1
Immunotherapy Against Amyloid-β in Alzheimer’s Disease: An Overview
Prins, N. D. (2016) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-3560-4_1 · Cited by 1
Revisiting the genetics of APOE
Carmona, S., Kun‐Rodrigues, C., Brás, J., & Guerreiro, R. J. (2017) · UCL Discovery (University College London) · Cited by 1
The Use of Monoclonal Antibodies in the Treatment of Alzheimer Disease
Moradi‐Sardareh, H., Moradi, M., Bordbar, E., Malekpour, M., Bagheri, S., Nakhodazadeh, N., Rahbar, S., & Asgarabadi, J. F. (2016) · Asian Pacific Journal of Cancer Biology · doi:10.31557/apjcb.2016.1.3.59-66 · Cited by 1
Drug Development for Alzheimer’s Disease: An Historical Perspective
Fillit, H. M., & Cummings, J. L. (2022) · Cambridge University Press eBooks · doi:10.1017/9781108975759.003 · Cited by 1
Therapieentwicklungen bei der Alzheimer-Krankheit
Grimmer, T. (2022) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-1802-4837 · Cited by 1
Anti-Amyloid-β Immunotherapy: A Leading Novel Avenue for Alzheimer's Disease
Babbar, R., Sharma, P., Sharma, T., Madaan, P., Arora, S., & Badavath, V. N. (2022) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557522666220524090354 · Cited by 1
Clinical Issues in Alzheimer Drug Development
Schneider, L. S. S. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00019-8 · Cited by 1
Translational Research: Preclinical to Healthy Volunteer to Patient
Tammara, B. K., Raje, S. V., McKeand, W. E., & Korth-Bradley, J. M. (2017) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-319-50042-3_11 · Cited by 1
Fukuchi, K., Yang, J., Kou, J., Song, M., Lalonde, R., Planque, S. A., & Paul, S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809813-4.00006-5 · Cited by 1
Tau Aggregation, Conformational Selection, and Inhibition
Holden, M. R. (2018) · Digital Commons - DU (University of Denver) · Cited by 1
Lee, M. J. (2019) · UKnowledge (University of Kentucky) · doi:10.13023/etd.2019.169 · Cited by 1
New Perspectives for Treatment in Alzheimer’s Disease
Loureiro, J. C., Silva, L. F. D. A. L. E., Pais, M. V., & Forlenza, O. V. (2022) · Springer eBooks · doi:10.1007/978-3-030-94383-7_10 · Cited by 1
Yeast as a Model for Studying Aβ Aggregation, Toxicity and Clearance
Bharadwaj, P. (2011) · Australasian Journal of Paramedicine · Cited by 1
Current and Prospective Treatments for Alzheimer's Disease (and Other Neurodegenerative Diseases)
Pedrini, S., Morici, M., & Martins, R. N. (2019) · Wiley eBooks · doi:10.1002/9781119356752.ch14 · Cited by 1
Singh, J., Sabbagh, M. N., Nair, A. K., Grundman, M., Kinney, G. G., Yuen, E., & Black, R. S. (2014) · Wiley eBooks · doi:10.1002/9781118730676.ch23 · Cited by 1
Self-citationPlowey, E. D., Abettan, J., Chou, P. C., Lye‐Barthel, M., Amaral, A. C. S., Sebalusky, J., Hamann, S., Srinivasan, J., Brown, R. Z., Fang, Q., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.30.702402 · Cited by 1
Charidimou, A. (2015) · UCL Discovery (University College London) · Cited by 1
Antibodies in Phase III Studies for Immunological Disorders
Ward, P., & Bodmer, M. (2014) · Wiley eBooks · doi:10.1002/9783527682423.ch29
Verlaufsmodifizierende Therapien der Alzheimer-Demenz
Heneka, M. T. (2010) · Der Nervenarzt · doi:10.1007/s00115-010-3000-1
Rational Therapeutics for Alzheimer's Disease and Other Dementias
Kowall, N. W. (2011) · Wiley eBooks · doi:10.1002/9781444344110.ch10
Real, V., & Ferreira, H. J. (2010) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Downer, B. G. (2014) · UKnowledge (University of Kentucky)
Mattsson, N., Portelius, E., Blennow, K., & Zetterberg, H. (2012) · Neurodegenerative Disease Management · doi:10.2217/nmt.11.75
Self-citationPanegyres, P. K., & Atkins, E. (2011) · Neuroscience & Medicine · doi:10.4236/nm.2011.23033
Why age (and timing) really matters in developing drugs for neurodegenerative disease
Morgan, D., & Smith, A. (2011) · Therapy · doi:10.2217/thy.11.49
Immunothérapie des maladies neurodégénératives: le temps est-il venu de changer de paradigme ?
Bachy, V. S., & Carnaud, C. (2011) · Bulletin de l Académie vétérinaire de France · doi:10.4267/2042/48075
La maladie d’Alzheimer : comment évaluer l’impact de la pathologie et des médicaments ?
Delrieu, J., & Vellas, B. J. (2010) · Therapies · doi:10.2515/therapie/2010057
Animal models of Alzheimer’s disease for preclinical research
Takahashi, H. (2010) · Folia Pharmacologica Japonica · doi:10.1254/fpj.136.6
Commentary on “Biomarkers in Alzheimer's disease drug development.” Can't live without 'em
Aisen, P. S. S. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.06.006
ABCA1, Apoe and apoA-I As Potential Therapeutic Targets for Treating Alzheimer’s Disease
Namjoshi, D., Stukas, S. K., & Wellington, C. L. (2011) · Neurodegenerative Disease Management · doi:10.2217/nmt.11.23
Targeting cytotoxic species in amyloid diseases
Persson, M. (2012)
Future Pharmacological Armamentaria in Management of Alzheimer Disease
Shah, M. H., Shah, H. D., & Chaudhari, V. (2013) · DOAJ (DOAJ: Directory of Open Access Journals)
IMMUNOTHERAPY IN COMBINATION WITH BEHAVIORAL ENRICHMENT IN A CANINE MODEL OF AGING
Davis, P. R. (2014) · UKnowledge (University of Kentucky)
Tin, G. (2014) · UWSpace (University of Waterloo)
Novel regulation of neuronal genes implicated in Alzheimer disease by microRNA
Long, J. M. (2013) · IUScholarWorks (Indiana University) · doi:10.7912/c2/2052
Beta-Amyloid-orientierte Therapien der Alzheimer-Krankheit
Grimmer, T. (2015) · DNP - Der Neurologe und Psychiater · doi:10.1007/s15202-015-0840-3
Motorisches und kognitives Training verbessert die Gedächtnisleistung
Müller, N. G., & Bittner, D. (2014) · NeuroTransmitter · doi:10.1007/s15016-014-0788-0
Alzheimer’s Disease Management: Current Therapy and Recent Drug Development
Abbasi, M., & Alam, M. R. (2016) · International Neuropsychiatric Disease Journal · doi:10.9734/indj/2016/24771
Neuroimaging and laboratory aspects
Pantoni, L., & Gorelick, P. B. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781139382694.012
Towards the Preclinical Treatment of Alzheimer Disease.
Iwatsubo, T. (2011) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.100.2089
Fluid Biomarkers and Diagnostics
Zetterberg, H., & Blennow, K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00021-6
Self-citationNeue Standards in der Bildgebung zerebraler Mikroangiopathien
Linn, J. (2015) · DNP - Der Neurologe und Psychiater · doi:10.1007/s15202-015-0987-y
Featured Article Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients
Siemers, E., Sundell, K. L., Carlson, C. D., Case, M. G., Sethuraman, G., Liu‐Seifert, H., Dowsett, S. A., Pontecorvo, M. J., Dean, R. A., & Demattos, R. B. (2016)
Future treatments of memory loss
Budson, A. E., & Solomon, P. R. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4160-3597-8.00017-2
Alzheimer’s Disease Mortality and Patient Retention in Clinical Trials
Arrighi, H. M. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-411464-7.00011-0
The Current Status of Alzheimer's Disease Treatment
Lanctôt, K. L., Kircanski, I., Chau, S. A., & Herrmann, N. (2012) · Frontiers in neuroscience · doi:10.1201/b11986-5
Immune Modulation of Inflammation in Neurodegenerative Diseases
Mahanian, M., Fiala, M., Mizwicki, M. T., & Cava, A. L. (2011) · Oxidative stress and disease · doi:10.1201/b11014-3
Imaging of hemorrhagic cerebral small vessel diseases
Linn, J., Greenberg, S. M., & Viswanathan, A. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781139382694.014
Soluble oligomeric Abeta42 affects microglia activation and mitochondrial respiration
Tan, C. (2015) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.6769
Effect of Gemini Surfactants on Amyloid Beta Aggregation
Bahmani, M. (2013) · UWSpace (University of Waterloo)
Metadata
- Authors
- Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., Mulnard, R., Barakos, J., Gregg, K. M., Liu, E., Lieberburg, I., Schenk, D., Black, R., & Grundman, M.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Butler Hospital (S.S.), Providence, RI; Brigham & Women's Hospital (R.S.), Boston, MA; University of Michigan (S.G.), Ann Arbor; UCL (N.C.F.), Institute of Neurology, London, UK; University of Göteborg (K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; VA Medical Center (M.R.), Seattle, WA; Cleo Roberts Center for Clinical Research/Sun Health Research Institute (M.S.), Sun City, AZ; Columbia University (L.S.H.), New York, NY; Baylor College of Medicine (R.D.), Houston, TX; Yale...
- Venue
- Neurology
- Published
- 2009-12-15
- Volume
- 73
- Issue
- 24
- Pages
- 2061-2070
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- PMC
- PMC2790221
- OpenAlex
- W2086572083
- Cited by
- 753
- References
- 40
- Citations by year
- 2026: 18 · 2025: 20 · 2024: 25 · 2023: 21 · 2022: 34 · 2021: 21 · 2020: 30 · 2019: 30 · 2018: 26 · 2017: 30 · 2016: 45 · 2015: 52 · 2014: 71 · 2013: 78 · 2012: 91
- FWCI
- 55.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Neurology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Pfizer
- National Institute for Health and Care Research (NF-SI-0508-10123)
- National Institutes of Health (5r03ag023916-02, 5r01ag007370-30, 1r41ns056856-01a2, 5u01ag024904-10)
- U.S. Public Health Service (UO1AGO24904)
- National Institute on Alcohol Abuse and Alcoholism (RL1AA017536)
- National Institute on Aging (U01-AG-024904, R01AG030457, R01AG14763, AG 08671, 1-R01-AG030457-01A1, P01AG007232, R01AG026114, U01AG016976, R01-AG007370, R43AG033474, U01AG010483, U01-AG 16976, 1-UO1-AG024904, 1 R03 AG023916-01A1, P01AG030004, P50AG008702, R01AG027435, R01AG017761, P01AG07232, P50AG008671, P30AG019610, P30 P3-AG 019610, P50AG005136, P50AG005134, U01AG032438, P50 AG08671, 5-U01-AG10483, AG06036-13, P50AG08702)
- National Heart, Lung, and Blood Institute (R01HL091099)
- National Institute of Mental Health (1 R01 MH58620-01A2, P50MH068789, R01MH058620)
- National Institute of Diabetes and Digestive and Kidney Diseases (IR21DK062098)
- National Institute of Neurological Disorders and Stroke (P01 NS 15655, P01NS015655, R01NS042859, T32NS007224)
- National Center for Research Resources (U54RR024350-01, P20RR020626)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- bapineuzumab, Alzheimer's disease, anti-amyloid beta monoclonal antibody, amyloid-beta, vasogenic edema, APOE ε4 carriers, cognitive decline, functional decline, dose escalation, treatment efficacy, drug safety
- MeSH terms
- Aged, Alzheimer Disease, Antibodies, Monoclonal, Brain, Brain Edema, Cognition, Dose-Response Relationship, Drug, Female, Heterozygote, Humans, Magnetic Resonance Imaging, Male, Severity of Illness Index, Biomarkers, Treatment Outcome, Apolipoprotein E4, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
